阿斯利康获瑞银上调目标价至238.85美元，市值超3200亿美元

Core Viewpoint - UBS analyst Matthew Weston maintains a "Buy" rating for AstraZeneca and raises the target price to $238.85, reflecting significant upside potential from the current stock price, which may positively influence investor sentiment [1]. Recent Events - On February 25, 2026, AstraZeneca announced that its oral GLP-1 candidate drug, elecoglipron, achieved primary endpoints in Phase 2 clinical trials for obesity and type 2 diabetes, supporting the initiation of Phase 3 trials, which is expected to strengthen the company's position in the weight loss drug market [1]. - On the same day, CEO Pascal Soriot's compensation for 2025 increased to £17.7 million, benefiting from the company's performance and stock price appreciation; AstraZeneca's market capitalization exceeded $320 billion, making it the highest-valued company on the London Stock Exchange [1]. - On February 27, 2026, multinational pharmaceutical companies like AstraZeneca accelerated the introduction of GLP-1 weight loss drug assets in China, indicating international recognition of the value of Chinese innovative drugs, which may expand the company's growth pipeline [1]. Stock Performance - As of February 27, 2026, AstraZeneca's stock price was $207.63, up 1.79% for the day, with a cumulative increase of 1.68% over the past five days; the total market capitalization reached $321.98 billion, with a year-to-date increase of 19.56% [2]. - The recent stock price fluctuation range was between $202.64 and $209.35, with stable trading activity [2].